Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18641539 | 0.75 | CYP1A2 (0.40) | KAT2B | |
| SCHEMBL14279802 | 0.74 | SLC6A3 (0.36) | KAT2B | |
| SCHEMBL24823223 | 0.71 | LOXL2 (0.36) | KAT2B | |
| SCHEMBL17080194 | 0.71 | KAT2B (0.31) | KAT2B | |
| SCHEMBL18641382 | 0.71 | — | — | |
| SCHEMBL7995338 | 0.71 | — | — | |
| SCHEMBL129913 | 0.71 | — | — | |
| SCHEMBL18667497 | 0.70 | SLC6A3 (0.40) | KAT2B | |
| SCHEMBL14471366 | 0.69 | KAT2B (0.35) | KAT2B | |
| SCHEMBL18641387 | 0.66 | LMNA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-10968211-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968211-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| CN-112094264-A | Hepatitis B core protein modulators | 组装生物科学股份有限公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-108347943-B | Hepatitis B core protein modulators | 组装生物科学股份有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-20200131168-A1 | HEPATITIS B CORE PROTEIN MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-20200131168-A1 | HEPATITIS B CORE PROTEIN MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-10377748-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377748-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180258084-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| EP-3349580-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017048950-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017048950-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | KAT2B 1546/4885 |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | KAT2B 1546/4885 |
| US-10377748-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | KAT2B 1546/4885 |
| US-10968211-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | KAT2B 1546/4885 |
| US-11814376-B2 | Hepatitis b core protein modulators | HAVCR2, FABP1, MAVS | KAT2B 1546/4885 |
| US-20200131168-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | KAT2B 1546/4885 |
| US-20180258084-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | KAT2B 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.